Journal articles on the topic 'ABCG2 inhibitors'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'ABCG2 inhibitors.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Henrich, Curtis J., Heidi R. Bokesch, Michael Dean, Susan E. Bates, Robert W. Robey, Ekaterina I. Goncharova, Jennifer A. Wilson, and James B. McMahon. "A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity." Journal of Biomolecular Screening 11, no. 2 (December 16, 2005): 176–83. http://dx.doi.org/10.1177/1087057105284576.
Full textKokubo, Shoji, Shinobu Ohnuma, Megumi Murakami, Haruhisa Kikuchi, Shota Funayama, Hideyuki Suzuki, Taiki Kajiwara, et al. "A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo." International Journal of Molecular Sciences 22, no. 22 (November 19, 2021): 12502. http://dx.doi.org/10.3390/ijms222212502.
Full textNatarajan, Karthika, Jasjeet Bhullar, Suneet Shukla, Mehmet Burcu, Suresh V. Ambudkar, and Maria R. Baer. "The Pim Kinase Inhibitor SGI-1776 Chemosensitizes Multidrug Resistant Cells by Both Inhibiting Drug Transport by ABCB1 and ABCG2 and Decreasing ABCB1 and ABCG2 Surface Expression On Cells That Overexpress Pim-1." Blood 120, no. 21 (November 16, 2012): 2462. http://dx.doi.org/10.1182/blood.v120.21.2462.2462.
Full textCurran, Sean, Toni-Marie Achilli, Elizabeth Leary, Benjamin T. Wilks, Marguerite M. Vantangoli, Kim Boekelheide, and Jeffrey R. Morgan. "A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration." TECHNOLOGY 03, no. 01 (March 2015): 54–63. http://dx.doi.org/10.1142/s2339547815500028.
Full textBarrera, Borja, Jon A. Otero, Estefanía Egido, Julio G. Prieto, Anna Seelig, Ana I. Álvarez, and Gracia Merino. "The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP." Antimicrobial Agents and Chemotherapy 56, no. 7 (April 16, 2012): 3535–43. http://dx.doi.org/10.1128/aac.06345-11.
Full textWang, Jing-Quan, Jonathan Y. Li, Qiu-Xu Teng, Zi-Ning Lei, Ning Ji, Qingbin Cui, Leli Zeng, Yihang Pan, Dong-Hua Yang, and Zhe-Sheng Chen. "Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells." Cancers 12, no. 2 (February 18, 2020): 466. http://dx.doi.org/10.3390/cancers12020466.
Full textStockmann, Philipp, Lydia Kuhnert, Wencke Leinung, Cathleen Lakoma, Birte Scholz, Svetlana Paskas, Sanja Mijatović, Danijela Maksimović-Ivanić, Walther Honscha, and Evamarie Hey-Hawkins. "The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors." Pharmaceutics 15, no. 1 (January 10, 2023): 241. http://dx.doi.org/10.3390/pharmaceutics15010241.
Full textInoue, Yutaka, Takashi Morita, Mari Onozuka, Ken-ichi Saito, Kazumi Sano, Kazuhiko Hanada, Masami Kondo, et al. "Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2." Cells 8, no. 7 (July 23, 2019): 763. http://dx.doi.org/10.3390/cells8070763.
Full textDi Micco, Simone, Veronica Di Sarno, Martina Rossi, Vincenzo Vestuto, Takumi Konno, Sara Novi, Mario Felice Tecce, et al. "In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents." International Journal of Molecular Sciences 24, no. 1 (December 31, 2022): 725. http://dx.doi.org/10.3390/ijms24010725.
Full textWu, Zhuo-Xun, Yuqi Yang, Qiu-Xu Teng, Jing-Quan Wang, Zi-Ning Lei, Jing-Qiu Wang, Sabrina Lusvarghi, Suresh V. Ambudkar, Dong-Hua Yang, and Zhe-Sheng Chen. "Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance." Cancers 12, no. 1 (January 12, 2020): 186. http://dx.doi.org/10.3390/cancers12010186.
Full textLe, Minh-Tri, Viet-Nham Hoang, Dac-Nhan Nguyen, Thi-Hoang-Linh Bui, Thien-Vy Phan, Phuong Nguyen-Hoai Huynh, Thanh-Dao Tran, and Khac-Minh Thai. "Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach." Molecules 26, no. 11 (May 23, 2021): 3115. http://dx.doi.org/10.3390/molecules26113115.
Full textStrouse, J. Jacob, Irena Ivnitski-Steele, Hadya M. Khawaja, Dominique Perez, Jerec Ricci, Tuanli Yao, Warren S. Weiner, et al. "A Selective ATP-Binding Cassette Subfamily G Member 2 Efflux Inhibitor Revealed via High-Throughput Flow Cytometry." Journal of Biomolecular Screening 18, no. 1 (August 24, 2012): 26–38. http://dx.doi.org/10.1177/1087057112456875.
Full textJuvale, Kapil, and Michael Wiese. "Design of inhibitors of BCRP/ABCG2." Future Medicinal Chemistry 7, no. 12 (August 2015): 1521–27. http://dx.doi.org/10.4155/fmc.15.83.
Full textHenrich, Curtis J., Robert W. Robey, Kentaro Takada, Heidi R. Bokesch, Susan E. Bates, Suneet Shukla, Suresh V. Ambudkar, James B. McMahon, and Kirk R. Gustafson. "Botryllamides: Natural Product Inhibitors of ABCG2." ACS Chemical Biology 4, no. 8 (July 10, 2009): 637–47. http://dx.doi.org/10.1021/cb900134c.
Full textHuang, Fang-Fang, Li Zhang, Yan-Hui Yu, Fang-ping Chen, Hui Zeng, Ting Niu, and Deng-shu Wu. "PTEN Regulated BCRP/ABCG2 and Side Population Through PI3K/Akt Pathway In Chronic Myeloid Leukemia." Blood 122, no. 21 (November 15, 2013): 5408. http://dx.doi.org/10.1182/blood.v122.21.5408.5408.
Full textvan Tellingen, Olaf, Mark C. de Gooijer, Stefanie Zuidema, Amber Meurs, Ceren H. Çitirikkaya, Nikkie Venekamp, and Jos H. Beijnen. "EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIER." Neuro-Oncology 22, Supplement_2 (November 2020): ii103. http://dx.doi.org/10.1093/neuonc/noaa215.426.
Full textTo, Kenneth K. W., Zhirong Zhan, Thomas Litman, and Susan E. Bates. "Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line." Molecular and Cellular Biology 28, no. 17 (June 23, 2008): 5147–61. http://dx.doi.org/10.1128/mcb.00331-08.
Full textKathawala, Rishil J., Claudia M. Espitia, Trace M. Jones, Shariful Islam, Pranav Gupta, Yun-Kai Zhang, Zhe-Sheng Chen, Jennifer S. Carew, and Steffan T. Nawrocki. "ABCG2 Overexpression Contributes to Pevonedistat Resistance." Cancers 12, no. 2 (February 12, 2020): 429. http://dx.doi.org/10.3390/cancers12020429.
Full textEadie, Laura N., Verity A. Saunders, Tamara M. Leclercq, Susan Branford, Deborah L. White, and Timothy P. Hughes. "The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2." Blood 126, no. 23 (December 3, 2015): 4841. http://dx.doi.org/10.1182/blood.v126.23.4841.4841.
Full textSilbermann, Katja, Jiyang Li, Vigneshwaran Namasivayam, Fabian Baltes, Gerd Bendas, Sven Marcel Stefan, and Michael Wiese. "Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists." Journal of Medicinal Chemistry 63, no. 18 (July 31, 2020): 10412–32. http://dx.doi.org/10.1021/acs.jmedchem.0c00961.
Full textSava, Georgina P., Hailing Fan, Rosemary A. Fisher, Sabrina Lusvarghi, Sunil Pancholi, Suresh V. Ambudkar, Lesley-Ann Martin, R. Charles Coombes, Lakjaya Buluwela, and Simak Ali. "ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942." Oncogene 39, no. 3 (September 17, 2019): 651–63. http://dx.doi.org/10.1038/s41388-019-1008-y.
Full textSorf, Ales, Simona Sucha, Anselm Morell, Eva Novotna, Frantisek Staud, Alzbeta Zavrelova, Benjamin Visek, Vladimir Wsol, and Martina Ceckova. "Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors." Cancers 12, no. 6 (June 16, 2020): 1596. http://dx.doi.org/10.3390/cancers12061596.
Full textWhite, Deborah L., Liu Lu, Timothy P. Clackson, Verity A. Saunders, and Timothy P. Hughes. "ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib." Blood 118, no. 21 (November 18, 2011): 2745. http://dx.doi.org/10.1182/blood.v118.21.2745.2745.
Full textLecerf-Schmidt, Florine, Basile Peres, Glaucio Valdameri, Charlotte Gauthier, Evelyn Winter, Léa Payen, Attilio Di Pietro, and Ahcène Boumendjel. "ABCG2: recent discovery of potent and highly selective inhibitors." Future Medicinal Chemistry 5, no. 9 (June 2013): 1037–45. http://dx.doi.org/10.4155/fmc.13.71.
Full textHenrich, C. J., R. W. Robey, H. R. Bokesch, S. E. Bates, S. Shukla, S. V. Ambudkar, M. Dean, and J. B. McMahon. "New inhibitors of ABCG2 identified by high-throughput screening." Molecular Cancer Therapeutics 6, no. 12 (December 7, 2007): 3271–78. http://dx.doi.org/10.1158/1535-7163.mct-07-0352.
Full textSim, Hong-May, Chong-Yew Lee, Pui Lai Rachel Ee, and Mei-Lin Go. "Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein)." European Journal of Pharmaceutical Sciences 35, no. 4 (November 2008): 293–306. http://dx.doi.org/10.1016/j.ejps.2008.07.008.
Full textNicolle, E., A. Boumendjel, S. Macalou, E. Genoux, A. Ahmed-Belkacem, P. A. Carrupt, and A. Di Pietro. "QSAR analysis and molecular modeling of ABCG2-specific inhibitors." Advanced Drug Delivery Reviews 61, no. 1 (January 2009): 34–46. http://dx.doi.org/10.1016/j.addr.2008.10.004.
Full textMichaelis, Martin, Florian Rothweiler, Thomas Nerreter, Mohsen Sharifi, Taravat Ghafourian, and Jindrich Cinatl. "Karanjin interferes with ABCB1, ABCC1, and ABCG2." Journal of Pharmacy & Pharmaceutical Sciences 17, no. 1 (March 10, 2014): 92. http://dx.doi.org/10.18433/j3bw2s.
Full textMountford, Joanne, Andrea Davies, Niove E. Jordanides, Athina Giannoudis, Claire M. Lucas, Sophia Hatziieremia, Robert J. Harris, et al. "Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters." Blood 112, no. 11 (November 16, 2008): 3205. http://dx.doi.org/10.1182/blood.v112.11.3205.3205.
Full textWu, Yao, Xin-Ying Gao, Xin-Hui Chen, Shao-Long Zhang, Wen-Juan Wang, Xie-Huang Sheng, and De-Zhan Chen. "Fragment-centric topographic mapping method guides the understanding of ABCG2-inhibitor interactions." RSC Advances 9, no. 14 (2019): 7757–66. http://dx.doi.org/10.1039/c8ra09789e.
Full textSafar, Zsolt, Emese Kis, Franciska Erdo, Joseph K. Zolnerciks, and Peter Krajcsi. "ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors." Expert Opinion on Drug Metabolism & Toxicology 15, no. 4 (March 16, 2019): 313–28. http://dx.doi.org/10.1080/17425255.2019.1591373.
Full textMealey, Katrina L., Sandamali Dassanayake, and Neal S. Burke. "Tyrosine Kinase Inhibitors Enhance Ciprofloxacin-Induced Phototoxicity by Inhibiting ABCG2." Oncology 87, no. 6 (2014): 364–70. http://dx.doi.org/10.1159/000366132.
Full textIshikawa, Toshihisa, Hiroshi Nakagawa, Yuichiro Hagiya, Naosuke Nonoguchi, Shin-ichi Miyatake, and Toshihiko Kuroiwa. "Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis." Advances in Pharmacological Sciences 2010 (2010): 1–13. http://dx.doi.org/10.1155/2010/587306.
Full textKochanek, Stanton J., David A. Close, Allen Xinwei Wang, Tongying Shun, Philip E. Empey, Julie L. Eiseman, and Paul A. Johnston. "Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy." SLAS DISCOVERY: Advancing the Science of Drug Discovery 24, no. 6 (April 30, 2019): 653–68. http://dx.doi.org/10.1177/2472555219844566.
Full textWu, Chung-Pu, Cheng-Yu Hung, Megumi Murakami, Yu-Shan Wu, Chun-Ling Lin, Yang-Hui Huang, Tai-Ho Hung, Jau-Song Yu, and Suresh V. Ambudkar. "P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells." Cancers 14, no. 9 (May 9, 2022): 2341. http://dx.doi.org/10.3390/cancers14092341.
Full textPeng, Hui, Jing Qi, Zizheng Dong, and Jian-Ting Zhang. "Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer Cells." PLoS ONE 5, no. 12 (December 7, 2010): e15276. http://dx.doi.org/10.1371/journal.pone.0015276.
Full textBoumendjel, Ahcène, Edwige Nicolle, Thomas Moraux, Bastien Gerby, Madeleine Blanc, Xavier Ronot, and Jean Boutonnat. "Piperazinobenzopyranones and Phenalkylaminobenzopyranones: Potent Inhibitors of Breast Cancer Resistance Protein (ABCG2)." Journal of Medicinal Chemistry 48, no. 23 (November 2005): 7275–81. http://dx.doi.org/10.1021/jm050705h.
Full textZhang, Shuzhong, Xinning Yang, and Marilyn E. Morris. "Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport." Molecular Pharmacology 65, no. 5 (April 20, 2004): 1208–16. http://dx.doi.org/10.1124/mol.65.5.1208.
Full textKraege, Stefanie, Katja Stefan, Sebastian C. Köhler, and Michael Wiese. "Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates." ChemMedChem 11, no. 22 (October 27, 2016): 2547–58. http://dx.doi.org/10.1002/cmdc.201600455.
Full textJuvale, Kapil, Jennifer Gallus, and Michael Wiese. "Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)." Bioorganic & Medicinal Chemistry 21, no. 24 (December 2013): 7858–73. http://dx.doi.org/10.1016/j.bmc.2013.10.007.
Full textde Gooijer, Mark C., Ping Zhang, Levi C. M. Buil, Stephan Freriks, Gang Li, Jos H. Beijnen, and Olaf van Tellingen. "DDRE-01. ACQUIRED AND INTRINSIC RESISTANCE TO VEMURAFENIB IN BRAFV600E-DRIVEN MELANOMA BRAIN METASTASES." Neuro-Oncology 22, Supplement_2 (November 2020): ii61. http://dx.doi.org/10.1093/neuonc/noaa215.246.
Full textLoh, Yen Siew, John D. Allen, Ammira Al-shabeeb, Ross D. Brown, Jia Li, Joshua Douglas, and Daniel Sze. "The Investigation of Mechanisms Underlying Hoechst 33342 Efflux in Myeloma ‘Side Population' Cells." Blood 114, no. 22 (November 20, 2009): 2759. http://dx.doi.org/10.1182/blood.v114.22.2759.2759.
Full textRudin, Charles M., Wanqing Liu, Apurva Desai, Theodore Karrison, Xuemin Jiang, Linda Janisch, Soma Das, et al. "Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity." Journal of Clinical Oncology 26, no. 7 (March 1, 2008): 1119–27. http://dx.doi.org/10.1200/jco.2007.13.1128.
Full textPetersen, Malene J., Xamuel L. Lund, Susan J. Semple, Bevan Buirchell, Henrik Franzyk, Michael Gajhede, Kenneth T. Kongstad, Jan Stenvang, and Dan Staerk. "Reversal of ABCG2/BCRP-Mediated Multidrug Resistance by 5,3′,5′-Trihydroxy-3,6,7,4′-Tetramethoxyflavone Isolated from the Australian Desert Plant Eremophila galeata Chinnock." Biomolecules 11, no. 10 (October 18, 2021): 1534. http://dx.doi.org/10.3390/biom11101534.
Full textCerveny, Lukas, Zuzana Ptackova, Marketa Durisova, and Frantisek Staud. "Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats." Reproductive Toxicology 79 (August 2018): 57–65. http://dx.doi.org/10.1016/j.reprotox.2018.05.008.
Full textBrummendorf, Tim H., Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost, et al. "Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib." Blood 114, no. 22 (November 20, 2009): 1724. http://dx.doi.org/10.1182/blood.v114.22.1724.1724.
Full textÖzvegy-Laczka, Csilla, Tamás Hegedűs, György Várady, Olga Ujhelly, John D. Schuetz, András Váradi, György Kéri, László Őrfi, Katalin Német, and Balázs Sarkadi. "High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter." Molecular Pharmacology 65, no. 6 (May 20, 2004): 1485–95. http://dx.doi.org/10.1124/mol.65.6.1485.
Full textPick, Anne, Henrik Müller, and Michael Wiese. "Structure–activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)." Bioorganic & Medicinal Chemistry 16, no. 17 (September 2008): 8224–36. http://dx.doi.org/10.1016/j.bmc.2008.07.034.
Full textAntoni, Frauke, Manuel Bause, Matthias Scholler, Stefanie Bauer, Simone A. Stark, Scott M. Jackson, Ioannis Manolaridis, et al. "Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)." European Journal of Medicinal Chemistry 191 (April 2020): 112133. http://dx.doi.org/10.1016/j.ejmech.2020.112133.
Full textAntoni, Frauke, David Wifling, and Günther Bernhardt. "Water-soluble inhibitors of ABCG2 (BCRP) – A fragment-based and computational approach." European Journal of Medicinal Chemistry 210 (January 2021): 112958. http://dx.doi.org/10.1016/j.ejmech.2020.112958.
Full text